Ensysce Biosciences and Quotient Sciences Announce a Partnership on the Development and Clinical Testing of Ensysce's PF614-MPAR, a Novel Opioid Designed to Prevent Abuse and Overdose
/PRNewswire/ -- Ensysce Biosciences, Inc., a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety, and Quotient...